SCHEMBL17290672

SCHEMBL17290672

CCOc1nn(-c2ccccc2)c(O)c1/C(C)=N/OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.41
▸ PDE4D Q08499 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ BCL2 P10415 1/20 0.36
▸ MDM2 Q00987 1/20 0.36
▸ MCL1 Q07820 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ NTRK1 P04629 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ NPY1R P25929 1/20 0.34
▸ NPY2R P49146 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17290674 1.00 LMNA (0.41) LMNAPDE4DSMN1; SMN2BCL2MDM2
SCHEMBL17290315 0.87 RAB9A (0.43) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL17290317 0.87 RAB9A (0.43) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL17290333 0.82 LMNA (0.49) LMNAPDE4DSMN1; SMN2BCL2MDM2
SCHEMBL17295099 0.82 LMNA (0.49) LMNAPDE4DSMN1; SMN2BCL2MDM2
SCHEMBL14886978 0.80 HPGD (0.47) PDE4DSMN1; SMN2MAPTALDH1A1NPC1
SCHEMBL14886976 0.80 HPGD (0.47) PDE4DSMN1; SMN2MAPTALDH1A1NPC1
SCHEMBL17290390 0.77 — —
SCHEMBL17290388 0.77 — —
SCHEMBL17290634 0.77 RIPK2 (0.39) LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682938-B2 Pyrazolone derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-06-20 — — US disclosed
EP-3148972-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS Cardioxyl Pharmaceuticals Inc. (US) 2017-04-05 — — EP disclosed
WO-2015183839-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-12-03 — — WO disclosed
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2015-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS TNNI3, PFKP, NOX5 LMNA 2480/4885PDE4D 407/4885SMN1; SMN2 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback